Cost-Effectiveness of Early Colectomy With Ileal Pouch-Anal Anastamosis Versus Standard Medical Therapy in Severe Ulcerative Colitis
- 1 July 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Annals of Surgery
- Vol. 256 (1), 117-124
- https://doi.org/10.1097/sla.0b013e3182445321
Abstract
Background: Inflammatory bowel diseases are costly chronic gastrointestinal diseases. We aimed to determine whether immediate colectomy with ileal pouch-anal anastamosis (IPAA) after diagnosis of severe ulcerative colitis (UC) was cost-effective compared to the standard medical therapy. Methods: We created a Markov model simulating 2 cohorts of 21-year-old patients with severe UC, following them until 100 years of age or death, comparing early colectomy with IPAA strategy to the standard medical therapy strategy. Deterministic and probabilistic analyses were performed. Results: Standard medical care accrued a discounted lifetime cost of $236,370 per patient. In contrast, early colectomy with IPAA accrued a discounted lifetime cost of $147,763 per patient. Lifetime quality-adjusted life-years gained (QALY-gained) for standard medical therapy was 20.78, while QALY-gained for early colectomy with IPAA was 20.72. The resulting incremental cost-effectiveness ratio (Δcosts/ΔQALY) was approximately $1.5 million per QALY-gained. Results were robust to one-way sensitivity analyses for all variables in the model. Quality-of-life after colectomy with IPAA was the most sensitive variable impacting cost-effectiveness. A low utility value of less than 0.7 after colectomy with IPAA was necessary for the colectomy with IPAA strategy to be cost-ineffective. Conclusions: Under the appropriate clinical settings, early colectomy with IPAA after diagnosis of severe UC reduces health care expenditures and provides comparable quality of life compared to exhaustive standard medical therapy.Keywords
This publication has 41 references indexed in Scilit:
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trialGut, 2011
- Outcome Following Infliximab Therapy in Children With Ulcerative ColitisAmerican Journal Of Gastroenterology, 2010
- Hospitalizations are increasing among minority patients with Crohnʼs disease and ulcerative colitisInflammatory Bowel Diseases, 2010
- Long-Term Direct Costs Before and After Proctocolectomy for Ulcerative Colitis: A Population-Based Study in Olmsted County, MinnesotaDiseases of the Colon & Rectum, 2009
- Direct Health Care Costs of Crohn's Disease and Ulcerative Colitis in US Children and AdultsGastroenterology, 2008
- The Direct and Indirect Cost Burden of Crohn's Disease and Ulcerative ColitisJournal of Occupational and Environmental Medicine, 2008
- The costs of Crohn's disease in the United States and other Western countries: a systematic reviewCurrent Medical Research and Opinion, 2007
- The Prevalence and Geographic Distribution of Crohn’s Disease and Ulcerative Colitis in the United StatesClinical Gastroenterology and Hepatology, 2007
- Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influencesGastroenterology, 2004
- CLINICAL OUTCOME OF THE FIRST TEN YEARS OF ULCERATIVE COLITIS AND PROCTITISThe Lancet, 1978